Introduction
============

Non-alcoholic fatty liver disease (NAFLD) has become one of the most common disorders due to its growing prevalence and latent progression in severe liver disease ([@b1-etm-0-0-8910]). During the past decades, consumption of fructose has risen markedly owing to the use of sucrose and high-fructose corn syrup in beverages and processed foods ([@b2-etm-0-0-8910]). Furthermore, increased fructose consumption is considered to play an important role in the development of metabolic diseases ([@b3-etm-0-0-8910]). In humans and other animals, chronically high consumption of fructose can cause various symptoms of the metabolic syndrome, such as impaired glucose tolerance, insulin resistance, hypertension, hypertriglyceridemia, dyslipidemia and fatty liver, which are associated with NAFLD ([@b4-etm-0-0-8910]).

Many studies have reported the underlying mechanisms of hepatic steatosis, which include hepatic fatty acid uptake, *de novo* lipogenesis, β-oxidation and export of hepatic lipid accumulation in fructose induced NAFLD ([@b4-etm-0-0-8910],[@b6-etm-0-0-8910],[@b7-etm-0-0-8910]). The increase in hepatic *de novo* lipogenesis is an important provider of lipids in fructose-induced fatty livers ([@b8-etm-0-0-8910],[@b9-etm-0-0-8910]). Fructose-derived precursors act as nutritional regulators of the transcription factors, including carbohydrate response element binding protein (ChREBP) and Sterol regulatory element-binding protein (SREBP) 1c ([@b10-etm-0-0-8910]) that regulate the expression of *de novo* lipogenesis genes. These two transcription factors activate the upstream and downstream targets: liver X receptor, acetyl-CoA carboxylase (ACC)1, fatty acid synthase and stearoyl-CoA desaturase (SCD)1 to upregulate hepatic lipogenic genes, which are associated with fructose-induced fatty acid synthesis ([@b11-etm-0-0-8910]). Also, impaired lipid disposal pathways including fatty acid oxidation (FAO), and export of lipids in very low-density lipoproteins (VLDL) contributed to the development of hepatic steatosis in the NAFLD ([@b18-etm-0-0-8910]). It has previously been revealed that several of the enzymes involved in hepatic FAO are influenced by PPARs, particularly PPARα ([@b19-etm-0-0-8910]). Moreover, high expression levels of PPARα and its target genes PGC1α and carnitine palmitoyl-transferase-1 (CPT1α) are responsible for mitochondrial and peroxisomal FAO to reduce hepatic lipid accumulation ([@b20-etm-0-0-8910]). Through the modulation of PPAR activity, the activity of SIRT1 controls hepatic lipid metabolism ([@b21-etm-0-0-8910],[@b22-etm-0-0-8910]). In addition, inflammation serves an important role in NAFLD. Previous studies have reported that NAFLD promotes liver inflammation to induce the downregulation of PPAR-α, which in turn increases the activation of the pro-inflammatory NF-κB as a priming signal leading to inflammasome activation ([@b23-etm-0-0-8910],[@b24-etm-0-0-8910]). As the increasing influence of NAFLD, more and more therapies focus on the comorbdities associated with NAFLD, particularly obesity, hyperglycemia, dyslipidemia and hypertension, or rely on diet and lifestyle changes ([@b25-etm-0-0-8910]). However, there are still no approved drugs for the treatment of NAFLD. Many natural products and herbal medicines have great antioxidant, anti-inflammatory, anti-apoptotic, and anti-adipogenic effects that allow them to be possible therapeutic agents in NAFLD treatment ([@b26-etm-0-0-8910],[@b27-etm-0-0-8910]).

Apple pomace is a by-product of apple processing used for beverages and desserts; however, due to the lack of awareness of apple pomace recycling, large amounts of resources are wasted ([@b28-etm-0-0-8910],[@b29-etm-0-0-8910]). Apple pomace is a rich source of various nutrients, including phytochemicals, vitamins and dietary minerals, and is particularly high in non-digestible carbohydrates and dietary fibers, indicating that it may elevate hepatic multi-unsaturated fatty acid content, increase circulating bile acids and attenuate hepatic steatosis ([@b30-etm-0-0-8910],[@b31-etm-0-0-8910]). In addition, apple pomace consumption has been demonstrated to improve lipid profiles ([@b31-etm-0-0-8910]) and endurance in the exercise performance of mice ([@b32-etm-0-0-8910]), as well as to ameliorate glucose metabolism in an oral glucose tolerance test in healthy volunteers ([@b33-etm-0-0-8910]).

Rosemary, which is an aromatic evergreen shrub grown in several parts of the world, is generally used as a spice and flavoring agent in food processing ([@b34-etm-0-0-8910]). It has also been reported that rosemary may regulate glucose and lipid metabolism in diabetic animals ([@b35-etm-0-0-8910]). Furthermore, rosemary extract along with moderate exercise training may ameliorate streptozotocin-induced oxidative damage, which help prevent the formation of diabetes-induced oxidative stress by upregulating superoxide dismutase (SOD), glutathione peroxidase (GSH-Px) and catalase levels in the erythrocytes of rats ([@b35-etm-0-0-8910]).

As apple pomace and rosemary (AR) individually attenuate metabolic disorders, it was hypothesized that a mixture of these compounds may have an anti-steatosis function in liver. Our recent study demonstrated that treatment with AR for 5 weeks attenuated chronic liquid fructose consumption-induced insulin resistance via modulation of sarcolemmal CD36 and glucose transporter 4 (GLUT4) in rats ([@b38-etm-0-0-8910]). Therefore, the present study examined whether AR may ameliorate hepatic steatosis in fructose-fed rats.

The aim of the present study was to investigate the effect of AR on fructose overconsumption-induced fatty liver and identify the underlying molecular mechanisms.

Materials and methods
=====================

### Animals, diet and experimental protocol

This study was approved by the Animal Ethics Committee of Chongqing Medical University (Chongqing, China). Male Sprague-Dawley (SD) rats (weight, 210-230 g; age, 12 weeks) and a standard diet were supplied by the Laboratory Animal Center of Chongqing Medical University. Rats were allowed free access to water and standard chow, and housed under specific pathogen-free conditions in an air-conditioned room (temperature, 21±1˚C; relative humidity, 55±5%) with a 12 h light/dark cycle. The animal model used in the present study was constructed as previously described ([@b39-etm-0-0-8910]). In total, 32 SD rats were initially divided into two groups, water control (n=6) and fructose (n=26). Rats in water control group had free access to water, and rats in fructose group had free access to 10% fructose solution (w/v, prepared every day). In the pilot experiment, it was observed that the animals treated with 20% fructose drank a reduced amount of fructose liquid compared with the water control group (data not shown), and it was considered that treatment with 20% fructose may cause dehydration in rats. Therefore, to investigate NAFLD induced by sugar-sweetened non-alcoholic beverages (\~10% sugar), 10% fructose was used in the study.

AR was made up of apple pomace (provided by Professor Johji Yamahara) and rosemary extract (Sami Labs Limited) at a ratio of 10:1 as previously described ([@b38-etm-0-0-8910]). Our previous study ([@b38-etm-0-0-8910]) reported that AR treatment at the doses of 100 and 500 mg/kg had a positive effect on the high level of plasma insulin and Homeostatic model assessment-index; however, AR exerted an improved anti-hepatic steatosis effect at 100 mg/kg compared with 500 mg/kg. Therefore, in the present study, rats in AR-treated groups were treated with 50 and 100 mg/kg of AR.

After 13 weeks, the fructose group was divided into three groups for the last 5 weeks: i) Fructose control (AR 0 mg/kg; n=8); ii) fructose AR 50 mg/kg (suspended in 5% gum arabic; gavage once daily; n=9); and iii) fructose AR 100 mg/kg (suspended in 5% gum arabic, gavage once daily; n=9). The rats in the water- and fructose-control groups received vehicle (5% gum arabic; cat. no. MC0124B1013J; Shanghai Bioengineering Co., Ltd.) alone.

Chow and fructose remaining in the feeder were weighed daily and the amount consumed per day was calculated. At the end of week 4 of treatment with vehicle or AR, the rats were fasted overnight, and blood samples (500 µl per rat) were collected to determine the plasma triglyceride using a and total cholesterol levels using a kit from Nanjing Jiancheng Bioengineering institute (cat. no. F001, F002). At the end of the experiment, the rats were anesthetized with inhaled isoflurane at an induction concentration of 3-4% and a maintenance concentration of 2-2.5%. Blood (5 ml per rat) was collected through the posterior orbital vein with a blood collection tube, and the rats were weighed and sacrificed by decapitation. The liver was collected and weighed, and segments of the liver were stored in liquid nitrogen and 4% formalin for subsequent testing.

### Determination of plasma and liver triglyceride and cholesterol

The plasma and liver levels of total cholesterol (cat. no. F002 Nanjing Jiancheng Bioengineering Institute) and triglyceride (cat. no. F001 Nanjing Jiancheng Bioengineering Institute) were measured enzymatically using commercial kits according to the manufacturer\'s instructions. The liver triglyceride and total cholesterol content was determined as previously described ([@b39-etm-0-0-8910],[@b40-etm-0-0-8910]). First, 100 mg of liver tissue was homogenated and dissolved in 2 ml 100% isopropanol. Then, following 3,000 x g centrifugation at 4˚C for 20 min, the supernatants were used to detect triglyceride and total cholesterol.

### Histological examination

To assess lipid droplet accumulation, a portion of the liver fixed with 4% formalin for 24 h was collected, and 6-µm frozen sections were cut and incubated with Oil Red O for 30 min at room temperature to examine the liver histology under a light microscope (BX-53; Olympus Corporation) at x40 magnification. In total, 40 fields in three individual sections were randomly selected, and the Oil Red O-stained and total tissue areas were measured using ImageJ 1.43 software (National Institutes of Health). The Oil Red O-stained to total tissue area ratio was calculated (%).

### Reverse transcription-quantitative PCR (RT-qPCR)

Total RNA was isolated from the liver tissues using RNAiso Plus (cat. no. 9109; Takara Biotechnology Co., Ltd.) according to the manufacturer\'s instructions. Subsequently, 1 µg of total RNA from each sample was used to generate cDNA by linear amplification using PrimeScript™ RT reagent Kit with gDNA Eraser (cat. no. RR047A; Takara Biotechnology Co., Ltd.). RNA from each sample was eliminated theDNAgenome at room temperature for 30 min and then reverse transcribed into cDNA at 37˚C for 15 min. The PCR reaction was performed in a total volume of 10 µl containing 1 µl cDNA template, 5 µl 2x TB Green Premix Ex Taq II (cat. no. RR420A; Takara Biotechnology Co., Ltd.), 0.4 µl forward primer, 0.4 µl reverse primer and 3.2 µl dH~2~O. The PCR program was as follows: Initial denaturation at 95˚C for 30 sec, followed by 40 cycles of 95˚C for 5 sec and 60˚C for 34 sec. The sequences of the primers used for RT-qPCR are listed in [Table I](#tI-etm-0-0-8910){ref-type="table"}. Relative gene expression data were analyzed using the 2^-ΔΔCq^ method ([@b44-etm-0-0-8910]). Gene expression for each sample was analyzed in duplicate and normalized against the internal control gene β-actin.

### Western blot analysis

Total protein from livers was prepared individually using the T-PER™ Tissue Protein Extraction Reagent (cat. no. 78510; Thermo Fisher Scientific, Inc.). Protein concentration was determined using the bicinchoninic acid protein concentration assay kit (cat. no. P0010S; Biyuntian Biotechnology Research Institute. Protein samples (30 µg/lane) were subjected to 10% SDS-PAGE and then electrotransferred to PVDF membranes (GE Healthcare Life Sciences). Membranes were incubated in blocking buffer (5% non-fat milk) for 2 h at room temperature and probed with the following antibodies: anti-SIRT1 (cat. no. 19A7AB4; 1:4,000; Abcam); anti-CPT1α (cat. no. ab83862; 1:800; Abcam), anti-PGC1α (cat. no. ab54481; 1:1,000; Abcam); anti-PPARα (cat. no. ab24509; Abcam); anti-adenosine 5\'-monophosphate (AMP)-activated protein kinase (AMPK) (cat. no. ab3759; 1:500; Abcam); anti-phospho-AMPK (cat. no. 2535; 1:800; Cell Signaling Technology, Inc.); NF-κB p65 (cat. no. ab16502; 1:1,000; Abcam) and tumor necrosis factor (TNF)-α (cat. no. ab66579; 1:500; Abcam) at 4˚C overnight. Subsequently, the membranes were incubated with horseradish peroxidase-conjugated goat anti-mouse (cat. no. BA1050; 1:5,000; Boster Biological Technology) and goat anti-rabbit IgG (cat. no. BA1054; 1:5,000; Boster Biological Technology) secondary antibodies at room temperature for 1.5 h. A polyclonal rabbit GAPDH antibody (cat. no. sc-AP0063; 1:10,000; Cell Signaling Technology, Inc.) and rabbit β-actin antibody (cat. no. 4970, 1:5,000; Cell Signaling Technology, Inc.) were used as the loading controls to normalize the signals obtained for proteins. Signal detection was performed using the ECL western blot detection kit (cat. no. M29050; Meng Bio) and the density was evaluated using ImageJ 1.43.

### Determination of malondialdehyde (MDA) and GSH-Px content, and total SOD (T-SOD) activity in the liver

First, 30 mg liver was rinsed with ice-cold 0.9% physiological saline, and the liver and 0.86% normal saline were mixed at the ratio of 1:9 or 1:90 (weight/volume) and homogenized to obtain 10 and 1% liver homogenates. After centrifugation at 1,200 x g for 15 min at 4˚C, the supernatant was used to detect T-SOD (cat. no. A001-3; Nanjing Jiancheng Bioengineering Institute) and succinate dehydrogenase (SDH) activity (cat. no. A022; Nanjing Jiancheng Bioengineering Institute), MDA (cat. no. A003-3; Nanjing Jiancheng Bioengineering Institute) and GSH-PX content (cat. no. A005; Nanjing Jiancheng Bioengineering Institute) according to the manufacturer\'s instructions.

### Statistical analysis

Data are presented as the mean ± SEM of at least three independent experiments. Data obtained from experiments with \>2 groups of animals were analyzed by one-way ANOVA followed by Bonferroni\'s post hoc test for n\>3 groups, while Student Newman-Keuls test was used for n\<3 groups. All the statistical analyses were performed using GraphPad Prism software (version 6.02; GraphPad Software, Inc.) P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### General parameters of rats in each group

Total chow intake of each rat over 5 weeks in the fructose groups decreased compared with that the water control group ([Table II](#tII-etm-0-0-8910){ref-type="table"}). However, no significant differences were observed in fructose and chow intake between the fructose control and the AR treatment groups ([Table II](#tII-etm-0-0-8910){ref-type="table"}). In addition, no differences were observed in the body weight, liver weight and ratio of liver to body weight among all groups at the end of the experiment ([Table II](#tII-etm-0-0-8910){ref-type="table"}). However, rats in the fructose groups had a higher plasma concentration of triglyceride compared with the water control group rats ([Table II](#tII-etm-0-0-8910){ref-type="table"}), but there was no significant difference in plasma total cholesterol concentration ([Table II](#tII-etm-0-0-8910){ref-type="table"}). It was also demonstrated that AR treatment did not suppress the increase in plasma triglyceride induced by fructose overconsumption ([Table II](#tII-etm-0-0-8910){ref-type="table"}).

### AR affects lipid accumulation in the livers of fructose-fed rats

Compared with the water control group, the rats in the fructose control group exhibited a higher hepatic triglyceride level ([Fig. 1B](#f1-etm-0-0-8910){ref-type="fig"}), whereas no significant difference was present in the total cholesterol concentration in the liver ([Fig. 1A](#f1-etm-0-0-8910){ref-type="fig"}). Furthermore, 100 mg/kg, but not 50 mg/kg of AR significantly diminished hepatic triglyceride accumulation induced by fructose overconsumption ([Fig. 1B](#f1-etm-0-0-8910){ref-type="fig"}). In accordance with these results, an increased Oil Red O staining area was observed during histological examination of liver sections from fructose-fed rats compared with that in the water control group, indicating excess lipid droplet accumulation induced by fructose feeding ([Fig. 1C-E](#f1-etm-0-0-8910){ref-type="fig"}). In rats treated with 100 mg/kg of AR, the Oil Red O staining area in the liver was lower compared with that in untreated fructose-fed rats ([Fig. 1C](#f1-etm-0-0-8910){ref-type="fig"}, [E](#f1-etm-0-0-8910){ref-type="fig"} and [F](#f1-etm-0-0-8910){ref-type="fig"}). Therefore, the histological and biochemical examination results in livers suggested that 100 mg/kg of AR attenuated hepatic lipid accumulation in fructose-fed rats.

### Expression of genes involved in fatty acid synthesis and metabolism

In the present study, fructose intake significantly stimulated hepatic upregulation of genes associated with fatty acid synthesis, such as SREBP1c, ACC1 and SCD1 (P\<0.05), but had little effect on genes involved in triglyceride synthesis, such as MGAT2, DGAT1 and DGAT2, in the livers of rats ([Fig. 2A](#f2-etm-0-0-8910){ref-type="fig"}). However, 100 mg/kg of AR treatment did not affect the expression levels of these genes. Therefore, these results suggested that AR-mediated amelioration of hepatic lipid accumulation may bypass the pathway of *de novo* lipogenesis.

### Expression of genes involved in fatty acid lipolysis and mobilization

Microsomal triglyceride transfer protein (MTTP) is the major lipid transfer protein that transfers triacylglycerols, phospholipids and cholesteryl esters *in vitro* between vesicles to assemble lipoproteins ([@b45-etm-0-0-8910],[@b8-etm-0-0-8910]). Adipose triglyceride lipase (ATGL) and hormone-sensitive lipase (HSL) can coordinate to liberate fatty acids, and the fatty acids are then transported into the mitochondria to undergo β-oxidation ([@b46-etm-0-0-8910]). The results of the present study indicated no significant differences in the gene expression levels of ATGL and MTTP among all groups ([Fig. 2B](#f2-etm-0-0-8910){ref-type="fig"}). Fructose feeding decreased the expression of HSL, but no significant changes were observed between the fructose control and fructose AR 100 mg/kg group ([Fig. 2B](#f2-etm-0-0-8910){ref-type="fig"}). Collectively, these results suggested that the anti-steatotic effect of AR may not be caused by modulation of genes associated with fatty acid lipolysis and mobilization.

### Expression of genes and proteins responsible for FAO

The RT-qPCR results demonstrated that the mRNA expression levels of CPT1α and SIRT1 were decreased in the livers of fructose-fed rats compared with those in the water control group, but significantly reversed by AR ([Fig. 3](#f3-etm-0-0-8910){ref-type="fig"}). However, AMPK mRNA expression was significantly decreased in the fructose control group compared with the water control group, but the decreation was little restored by AR ([Fig. 3](#f3-etm-0-0-8910){ref-type="fig"}). The results of western blotting also identified that AR treatment increased the expression of pAMPK/AMPK, CPT1α, PPARα, SIRT1 and PGC1α at the protein level in the livers of fructose-fed rats (P\<0.05; [Fig. 4](#f4-etm-0-0-8910){ref-type="fig"}), suggesting that the restoration of PPARα and PGC-1α at translation, but not transcription level, improved liver lipid accumulation ([Fig. 4C](#f4-etm-0-0-8910){ref-type="fig"} and [F](#f4-etm-0-0-8910){ref-type="fig"}).

Lipid peroxidation was measured as the content of MDA in whole homogenates of the rat livers among the three groups. In addition, the activities of enzymes responsible for mitochondrial function, including SOD, GSH and SDH, were detected. Compared with the water control group, GSH, which was used to assess oxidative stress in the liver, decreased significantly after fructose treatment alone, whereas treatment with AR had no effect on GSH compared with the fructose control group ([Fig. 5A](#f5-etm-0-0-8910){ref-type="fig"}). It was also demonstrated that fructose administration increased SDH activity in the liver, and AR treatment had a minimal effect on this ([Fig. 5B](#f5-etm-0-0-8910){ref-type="fig"}). Furthermore, no differences in the MDA and SOD content were observed under any condition ([Fig. 5C](#f5-etm-0-0-8910){ref-type="fig"} and [D](#f5-etm-0-0-8910){ref-type="fig"}).

### Expression of genes responsible for gluconeogenesis and insulin signaling

Gluconeogenesis occurs mainly in the liver and is mediated by glucagon, and can be counteracted by insulin; insulin triggers the phosphorylation of enzymes and regulatory proteins via protein kinase A, resulting in the inhibition of glycolysis ([@b47-etm-0-0-8910]). Insulin can also induce the cascade of genes required for the synthesis of fatty acids ([@b11-etm-0-0-8910],[@b48-etm-0-0-8910]). Next, the expression of the key gluconeogenic enzymes phosphoenolpyruvate carboxykinase (PEPCK) and genes associated with the insulin signaling pathway were examined. It was identified that PEPCK, glucose-6-phosphatase 3 and insulin receptor substrate mRNA expression levels were significantly decreased after fructose alone compared with those in the water control group, but AR treatment had a minimal effect on these genes compared with the fructose control group ([Fig. 6](#f6-etm-0-0-8910){ref-type="fig"}). In addition, the expression levels of relevant genes, such as GLUT 8 and fibroblast growth factor 21, exhibited no significant differences under these conditions ([Fig. 6](#f6-etm-0-0-8910){ref-type="fig"}).

### Expression of proteins associated with inflammation

The overconsumption of fructose provokes metabolic changes that result in a chronic low-grade inflammation ([@b49-etm-0-0-8910]). The expression levels of inflammation-related proteins were assessed, and the results demonstrated that fructose induced NF-κB p65 upregulation compared with the water control group; in addition, rats treated with AR exhibited lower expression of NF-κB p65 compared with fructose group ([Fig. 7](#f7-etm-0-0-8910){ref-type="fig"}). The expression of TNF-α showed no significant differences under all the conditions. Collectively, the result indicated that AR-mediated amelioration of fructose-induced hepatic lipid accumulation may be associated with the inflammatory pathway.

Discussion
==========

It has been revealed that apple pomace improves metabolic abnormalities ([@b28-etm-0-0-8910],[@b31-etm-0-0-8910]). Furthermore, our previous study reported that AR suppressed insulin resistance via modulation of sarcolemmal CD36 and GLUT-4 in fructose-fed rats ([@b38-etm-0-0-8910]). In the present study, it was indicated that AR decreased chronic liquid fructose consumption-induced hepatic steatosis, as demonstrated by the decrease in liver triglyceride concentrations and attenuation in Oil Red O staining area in the livers of rats. However, AR treatment did not affect body or liver weight and had minimal effects on plasma and liver concentrations of total cholesterol. Therefore, these findings suggested a specific anti-steatosis effect of AR in rats.

The present study investigated the expression of genes involved in *de novo* lipogenesis, fatty acid lipolysis and mobilization, gluconeogenesis and the insulin signaling pathway; however, none of these were affected by AR treatment. Thus, it was speculated that AR treatment diminished fructose-induced hepatic lipid deposition independently of any of the mechanisms listed above.

The results of the present study also suggested that AR treatment resulted in reduced protein expression levels of hepatic PPARα and CPT1α in fructose-fed rats compared with those in the untreated rats. Furthermore, via the stimulation of the nuclear transcription factor PPARα receptor, AR treatment activated PGC1α signaling for transcriptional regulation of a number of proteins that alter metabolism within mitochondria. PGC-1a can be deacetylated by SIRT1, and form a complex with PPARa, leading to increased FA oxidation ([@b50-etm-0-0-8910]). Moreover, when FAO increases, the activity of SIRT1 also increases ([@b22-etm-0-0-8910]). The direct SIRT1 substrate PGC1α, which is deacetylated and hyperactived by SIRT1, cooperates with PPARα to induce mitochondrial biogenesis and β-oxidation reactions ([@b51-etm-0-0-8910]). The results of the present study indicated that the expression levels of SIRT1, PGC1α and PPARα were increased by AR treatment, suggesting that AR-induced amelioration of hepatic steatosis may be associated with enhanced mitochondrial biogenesis and β-oxidation. However, AR treatment had no effect on the factors associated with oxidative stress such as MDA, SOD, GSH and SDH, which may be due to the short duration of the experimental period.

There are seven known SIRT enzymes, SIRT1-SIRT7, in mammals ([@b52-etm-0-0-8910]). SIRT3-SIRT5 are located in the mitochondria, whereas SIRT1, SIRT6 and SIRT7 are principally located in the nucleus, and the majority of SIRT2 is located in the cytoplasm ([@b55-etm-0-0-8910],[@b56-etm-0-0-8910]). The homeostasis of NAD^+^ has been reported to serve a vital role in the inception of fatty liver by modulating mitochondrial efficiency ([@b57-etm-0-0-8910]). Furthermore, SIRTs utilize NAD^+^ as a co-substrate to eliminate acetyl moieties from lysines on histones and proteins ([@b54-etm-0-0-8910]). Among them, SIRT1 fulfills the key criteria to be considered a NAD^+^ sensor ([@b58-etm-0-0-8910]). Moreover, through the modulation of PPAR activity, SIRT1 controls hepatic lipid metabolism ([@b21-etm-0-0-8910],[@b22-etm-0-0-8910]). In line with the co-regulation of NAD^+^ and SIRT1, a sufficient NAD^+^ pool maintains metabolic health by restoring SIRT1 activity and signaling ([@b58-etm-0-0-8910]). Thus, this may be a mechanism that explains how AR elevates intracellular SIRT1 levels and activates NAD^+^-dependent SIRT-mediated signaling pathways in metabolism-related chronic diseases ([@b59-etm-0-0-8910]). Therefore, it was speculated in the present study that AR may restore the expression of SIRT1 by regulating the NAD^+^ homeostasis pathway.

Previous studies have reported that PGC1α is a key factor coordinating the gene expression that activates the mitochondrial oxidative metabolism ([@b60-etm-0-0-8910]). Activated AMPK binds to the promoter of PGC1α and is subsequently activated by SIRT1 to increase the expression of genes that are critical to FAO ([@b61-etm-0-0-8910]). In addition, SIRT1 deacetylates its substrate PGC1α to become hyperactive ([@b52-etm-0-0-8910]), and associates with PPARα on target promoters to facilitate gene transcription in order to control hepatic lipid metabolism ([@b21-etm-0-0-8910],[@b52-etm-0-0-8910]). PPARα is the principal regulator of FAO metabolism via the transcriptional induction of several enzymes, such as acyl-CoA dehydrogenase medium chain, CPT1α and CPT2([@b62-etm-0-0-8910]). CPT1α, which catalyze the rate-limiting step in mitochondrial FAO ([@b63-etm-0-0-8910]). Therefore, it was speculated in the present study that SIRT1 may directly regulate PGC1α, thus restoring the expression of CPT1α and exerting hepatoprotective effects, which may be partially dependent on the antioxidant capacity of AR. In addition, moderate expression of SIRT1 induces resistance to oxidative stress ([@b63-etm-0-0-8910]), and agonist-dependent SIRT1 activation can suppress the NF-κB transcriptional activity, which results in subdued oxidative and inflammatory pathology and enhanced antioxidant status in chronic chagasic cardiomyopathy ([@b64-etm-0-0-8910]). In line with these findings, the present results suggested that AR treatment reversed the decreased SIRT1 expression in the liver of fructose-fed rats and downregulated the expression of NF-κB. A previous study has provided genetic evidence for a functional crosstalk of nuclear factor erythroid 2-related factor (Nrf2) and NF-κB p65 in hepatocytes, which protects the liver from inflammation ([@b65-etm-0-0-8910]). Another study has reported crosstalk between SIRT1 and Nrf2 as SIRT1 is reduced in Nrf2^-^/^-^ murine fibroblasts, and the increase in Nrf2 and Nrf2-dependent gene expression is associated with a significant increase in heart SIRT1 in senescence-accelerated mouse-prone 8 mice ([@b66-etm-0-0-8910]). However, further investigation is required to assess the expression of Nrf2 and to further elucidate the function of SIRT1 as well as the underlying mechanisms of the metabolic action of AR.

In conclusion, the results of the present study suggested that treatment with a mixture of AR improves chronic fructose consumption-induced hepatic steatosis in rats by enhancing FAO and suppressing inflammation. Moreover, there are some limitations in the present study. Firstly, although the mixture of apple pomace and rosemary extract could ameliorate hepatic steatosis in fructose-induced NAFLD, additional studies are required to investigate the individual contributions of the two components during this process. Additionally, it is necessary to consider the potentially important sex-specific effects in metabolic improvement. However, the present study provided novel evidence regarding the use of AR as a functional food and drug for the prevention and treatment of metabolism-associated disorders.
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![AR affects lipid accumulation in the livers of fructose-fed rats. (A) Liver concentration of total cholesterol. (B) Liver concentration of triglycerides. (C) Oil Red O staining area and (D-F) representative images of Oil Red O staining in the liver of rats from (D) water, (E) fructose control and (F) fructose AR (100 mg/kg) groups. Data are presented as the mean ± SEM, n=6-9 per group. Water, water control; Fructose, contains fructose control, fructose AR (50 mg/kg) and fructose AR (100 mg/kg). Scale bar, 50 µm. ^\*^P\<0.05 vs. fructose control. AR, apple pomace and rosemary.](etm-20-03-1975-g00){#f1-etm-0-0-8910}

![Expression of genes involved in fatty acid synthesis and metabolism, as well as lipolysis and mobilization. (A and B) Expression levels of genes responsible for (A) lipogenesis and (B) lipid mobilization in the livers of rats from each group were determined by reverse transcription-quantitative PCR and normalized to β-actin. Data are presented as the mean ± SEM, n=6-9 per group. ^\*^P\<0.05 vs. fructose control. CHREBP, carbohydrate response element binding protein; LPK, liver pyruvate kinase; LXR, liver X receptor; SREBP-1c, sterol regulatory element-binding protein-1c; ACC, acetyl-CoA carboxylase; FAS, fatty acid synthase; SCD-1, stearoyl-CoA desaturase-1; DGAT-1, diacylglycerol acyltransferases-1; DGAT-2, diacylglycerol acyltransferases-2; MGAT-2, monoacylglycerol acyltransferase-2; HSL, hormone-sensitive lipase; ATGL, adipose triglyceride lipase; MTTP, microsomal triglyceride transfer protein; AR, apple pomace and rosemary.](etm-20-03-1975-g01){#f2-etm-0-0-8910}

![Expression of genes involved in fatty acid oxidation. Expression levels of genes responsible for gluconeogenic and insulin signaling in the livers of rats from each group were determined by reverse transcription-quantitative PCR and normalized to β-actin. Data are presented as the mean ± SEM, n=6-9 per group. ^\*^P\<0.05 vs. fructose control. AMPK, adenosine 5\'-monophosphate-activated protein kinase; ACO, aconitase; PPARα, peroxisome proliferator-activated receptor α; CPT1, carnitine palmitoyl-transferase-1; SIRT1, sirtuin 1, PGC-1α, peroxisome proliferator-activated receptor-γ coactivator-1α; AR, apple pomace and rosemary.](etm-20-03-1975-g02){#f3-etm-0-0-8910}

![Expression of proteins involved in fatty acid oxidation. (A) A representative image of western blot analysis of SIRT1, PGC-1α, CPT-1α, PPAR-α, pAMPK and AMPK in the liver. (B) SIRT1 protein expression. (C) PGC-1α protein expression. (D) Ratio of pAMPK/AMPK protein expression levels. (E) CPT-1α protein expression. (F) PPAR-α protein expression. Protein expression was analyzed by western blotting and normalized to GAPDH and β-actin. Data are presented as the mean ± SEM, n=6-9 per group. Water, water control; Fructose, contains fructose control and fructose AR (100 mg/kg). ^\*^P\<0.05 vs. fructose control. SIRT1, sirtuin 1; PGC-1α, peroxisome proliferator-activated receptor-γ coactivator-1α; PPARα, peroxisome proliferator-activated receptor-α; CPT1, carnitine palmitoyl-transferase-1; pAMPK, phospho-adenosine 5\'-monophosphate (AMP)-activated protein kinase; AMPK, adenosine AMP-activated protein kinase; AR, apple pomace and rosemary.](etm-20-03-1975-g03){#f4-etm-0-0-8910}

![Detection of mitochondrial enzyme functional activity. (A-D) Contents of (A) GSH-Px, (B) SDH, (C) MDA and (D) SOD in the livers of rats from each group. Data are presented as the mean ± SEM, n=6-9 per group. Water, water control; fructose, contains fructose control and fructose AR (100 mg/kg). ^\*^P\<0.05 vs. fructose control group. GSH-Px, glutathione peroxidase; SDH, succinate dehydrogenase; MDA, malondialdehyde; SOD, superoxide dismutase; AR, apple pomace and rosemary.](etm-20-03-1975-g04){#f5-etm-0-0-8910}

![Expression of genes involved in gluconeogenesis and insulin signaling. Expression levels of genes responsible for gluconeogenic and insulin signaling in the livers of rats from each group were determined by reverse transcription-quantitative PCR and normalized to β-actin. Data are presented as the mean ± SEM, n=6-9 per group. Water, water control; Fructose, contains fructose control and fructose AR (100 mg/kg). ^\*^P\<0.05 vs. fructose control group. PEPCK, phosphoenolpyruvate carboxykinase; G6PC3, glucose-6-phosphatase 3; GLUT8, glucose transporter 8; FGF21, fibroblast growth factor-21; IRS, insulin receptor substrate; AR, apple pomace and rosemary.](etm-20-03-1975-g05){#f6-etm-0-0-8910}

![Expression of proteins involved in liver inflammation. (A) A representative image of western blot analysis of NF-κB and TNF-α in liver. (B) TNF-α protein expression. (C) NF-κB protein expression. Protein expression was analyzed by western blotting and normalized to β-actin. Data are presented as the mean ± SEM, n=6-9 per group. Water, water control; Fructose, contains fructose control and fructose AR (100 mg/kg). ^\*^P\<0.05 vs. fructose control group. TNF-α, tumor necrosis factor-α; AR, apple pomace and rosemary.](etm-20-03-1975-g06){#f7-etm-0-0-8910}

###### 

Primers sequences of reverse transcription-quantitative PCR assays.

  Gene                          Sequences (5\'-3\')           GenBank code   Product length, bp   Tm
  ----------------------------- ----------------------------- -------------- -------------------- ------
  β-actin                       F: ACGGTCAGGTCATCACTATCG      NM031144       155                  60˚C
  R: GGCATAGAGGTCTTTACGGATG                                                                       
  ACC-1                         F: AACATCCCGCACCTTCTTCTAC     NM022193       138                  60˚C
  R: CTTCCACAAACCAGCGTCTC                                                                         
  ACO                           F: CCCAAGACCCAAGAGTTCATTC     NM017340       113                  60˚C
  R: TCACGGATAGGGACAACAAAGG                                                                       
  ChREBP                        F: GAAGACCCAAAGACCAAGATGC     FN432819       169                  60˚C
  R: TCTGACAACAAAGCAGGAGGTG                                                                       
  CPT-1α                        F: CTGCTGTATCGTCGCACATTAG     NM031559       120                  60˚C
  R: GTTGGATGGTGTCTGTCTCTTCC                                                                      
  FAS                           F: ACCTCATCACTAGAAGCCACCAG    NM017332       116                  60˚C
  R: GTGGTACTTGGCCTTGGGTTTA                                                                       
  LPK                           F: GACCCGAAGTTCCAGACAAGG      NM012624       110                  60˚C
  R: ATGAGCCCGTCGTCAATGTAG                                                                        
  PPARα                         F: GTCATCACAGACACCCTCTCCC     HM117640       124                  60˚C
  R: TGTCCCCACATATTCGACACTC                                                                       
  SCD-1                         F: CAGTTCCTACACGACCACCACTA    NM139192       111                  60˚C
  R: GGACGGATGTCTTCTTCCAGAT                                                                       
  SREBP-1c                      F: CTGTCGTCTACCATAAGCTGCAC    NM001276707    121                  60˚C
  R: ATAGCATCTCCTGCACACTCAGC                                                                      
  LXR                           F: AGAAACTGAAGCGTCAAGAAGAGG   NM031627       131                  60˚C
  R: GGCAGCCACCAACTTCTCAA                                                                         
  DGAT1                         F: GGCAGCCACCAACTTCTCAA       NM053437       136                  60˚C
  R: CAGCATCACCACGCACCAAT                                                                         
  DGAT2                         F: CCTGGCAAGAACGCAGTCAC       NM001012345    137                  60˚C
  R: CCTGGCAAGAACGCAGTCAC                                                                         
  MGAT2                         F: GCGACAAAGGAAGAACGACG       NM053604       105                  60˚C
  R: GCGACAAAGGAAGAACGACG                                                                         
  HSL                           F: TTCGGGGAACACTACAAACGC      NM012859       179                  60˚C
  R: AGCACCTCGATCTCCGTGATATTC                                                                     
  ATGL                          F: CTGATGACCACCCTTTCCAAC      NM001108509    169                  60˚C
  R: AGATGCTACCTGTCTGCTCCTTC                                                                      
  AMPK                          F: CTCAACCGTTCTATTGCCACTCT    NM019142       179                  60˚C
  R: AGGAAAGAGGTAACTGGGCAAAT                                                                      
  PGC-1α                        F: TGACCACAAACGATGACCCTC      NM031347       207                  60˚C
  R: GACTGCGGTTGTGTATGGGAC                                                                        
  G6PC3                         F: GAGTGGCTCAACCTCGTCTTC      NM176077       112                  60˚C
  R: AAGGGAACTGGTGAATCTGGAC                                                                       
  IRS                           F: CTTCTGTTACACCTCAAGGGGC     NM012969       120                  60˚C
  R: GGTTATGGTTGGGACTTAGGTTCA                                                                     
  PEPCK                         F: CGAGAGATCAACTGGGAAGAGC     NM001276721    136                  60˚C
  R: TGTCAGCGAACGATAGCCG                                                                          
  MTTP                          F: TTCATTCAGCACCTCCGCACTTC    NM001107727    123                  60˚C
  R: AGTCCAGGATGGCTTCCAGTGAG                                                                      
  FGF21                         F: TCTCCTGCTGCCTGTCTTCCTG     NM130752       129                  60˚C
  R: TCGGTGTCCTGGTCGTCATCTG                                                                       
  SIRT1                         F: AGGGAACCTCTGCCTCATCTAC     NM001372090    99                   60˚C
  R: GGCATACTCGCCACCTAACCT                                                                        

F, forward; R, reverse; Tm, temperature.

###### 

General parameters of rats in each group.

  Parameter                          Water control                                              Fructose control   Fructose AR (50 mg/kg)   Fructose AR (100 mg/kg)
  ---------------------------------- ---------------------------------------------------------- ------------------ ------------------------ -------------------------
  Chow intake, g/rat/5 weeks         821.0±17.0^[a](#tfn1-etm-0-0-8910){ref-type="table-fn"}^   457.3±17.3         476.0±17.7               485.0±17.3
  Fructose intake, g/rat/5 weeks     0                                                          384.0±12.0         394.3±11.3               377.8±11.7
  Energy intake, kcal                3447±30                                                    3461±32            3583±32                  3547±33
  Body weight, g                     362.2±17.0                                                 361.0±14.9         360.7±16.3               365.0±16.2
  Liver weight, g                    9.3±0.4                                                    9.5±0.4            10.2±0.5                 9.8±0.4
  Liver/body weight, mg/g            25.7±0.6                                                   26.8±0.7           26.9±1.3                 27.0±1.1
  Plasma total cholesterol, mmol/l   2.1±0.4                                                    2.4±0.2            2.4±0.2                  2.3±0.2
  Plasma triglyceride, mmol/l        0.5±0.04^[a](#tfn1-etm-0-0-8910){ref-type="table-fn"}^     0.8±0.03           0.8±0.05                 0.8±0.03

Data are presented as the mean ± SEM, n=6-9 per group.

^a^P\<0.05 vs. fructose control group. AR, apple pomace and rosemary.
